Capital International Investors
RARE icon

Capital International Investors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Capital International Investors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-967,357
Closed -$44.6M – 449
2023
Q2 		$44.6M Sell
967,357
-327,203
-25% -$15.2M 0.01% 342
2023
Q1 		$51.9M Hold
1,294,560
– – 0.01% 333
2022
Q4 		$60M Sell
1,294,560
-2,096,522
-62% -$82.5M 0.02% 318
2022
Q3 		$140M Sell
3,391,082
-21,324
-0.6% -$1.1M 0.04% 263
2022
Q2 		$204M Buy
3,412,406
+67,380
+2% +$4.15M 0.06% 244
2022
Q1 		$243M Sell
3,345,026
-2,024,748
-38% -$141M 0.06% 242
2021
Q4 		$452M Sell
5,369,774
-295,419
-5% -$24M 0.1% 186
2021
Q3 		$511M Buy
5,665,193
+208,069
+4% +$18.8M 0.12% 168
2021
Q2 		$520M Buy
5,457,124
+33,002
+0.6% +$3.44M 0.12% 168
2021
Q1 		$618M Sell
5,424,122
-837,184
-13% -$114M 0.16% 140
2020
Q4 		$867M Buy
6,261,306
+63,357
+1% +$7.52M 0.24% 114
2020
Q3 		$509M Buy
6,197,949
+112,817
+2% +$9.35M 0.16% 134
2020
Q2 		$476M Sell
6,085,132
-47,062
-0.8% -$3.12M 0.16% 131
2020
Q1 		$272M Buy
6,132,194
+89,619
+1% +$4.65M 0.11% 148
2019
Q4 		$258M Buy
6,042,575
+33,818
+0.6% +$1.4M 0.09% 168
2019
Q3 		$257M Buy
6,008,757
+390,195
+7% +$21.2M 0.1% 165
2019
Q2 		$357M Buy
5,618,562
+50,013
+0.9% +$3.18M 0.14% 148
2019
Q1 		$386M Buy
5,568,549
+978,695
+21% +$55.9M 0.17% 138
2018
Q4 		$200M Buy
4,589,854
+229,963
+5% +$12.6M 0.1% 167
2018
Q3 		$333M Buy
4,359,891
+755,127
+21% +$61.4M 0.15% 150
2018
Q2 		$277M Buy
3,604,764
+13,718
+0.4% +$886K 0.31% 105
2018
Q1 		$183M Buy
3,591,046
+12,259
+0.3% +$617K 0.21% 121
2017
Q4 		$166M Buy
3,578,787
+683,306
+24% +$33.5M 0.19% 127
2017
Q3 		$154M Buy
2,895,481
+520,496
+22% +$30.8M 0.18% 137
2017
Q2 		$148M Buy
2,374,985
+198,252
+9% +$11.9M 0.2% 133
2017
Q1 		$148M Buy
2,176,733
+1,175,879
+117% +$89.6M 0.2% 131
2016
Q4 		$70.4M Buy
1,000,854
+520,554
+108% +$36.9M 0.1% 170
2016
Q3 		$34.1M Buy
+480,300
New +$30.7M 0.05% 215

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Capital International Investors's RARE Position: Q3 2023 in Review

Capital International Investors sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2023, closing a stake of 967,357 shares — an estimated $44.6M sold.

Capital International Investors first reported a position in RARE in Q3 2016 and held it in 28 quarters. The position peaked at $867M in Q4 2020. 220 funds tracked by Wall St. Rank hold RARE as of Q3 2023.

  • Capital International Investors reported no remaining Ultragenyx Pharmaceutical position as of Q3 2023 after selling out during the quarter.
  • Capital International Investors sold 967,357 Ultragenyx Pharmaceutical shares in Q3 2023, an estimated $44.6M.
  • Capital International Investors first reported a position in Ultragenyx Pharmaceutical in Q3 2016 and held it in 28 quarters.
  • Capital International Investors's Ultragenyx Pharmaceutical position peaked at $867M in Q4 2020.
  • 220 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2023.

Based on Capital International Investors's 13F filing for Q3 2023, filed 13 Nov 2023.